Search research articles
Contact Us
Filters
Showing results (161-170 of 327) with videos related to
Page
of 33
Sort By:
The Journal of Molecular Diagnostics : JMD
|
December 4, 2015
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma
Carrie C Lubitz, Sareh Parangi, Tammy M Holm, et al.
Journal of the American Academy of Dermatology
|
March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study
Bonnie W Leung, Guihong Wan, Nga Nguyen, et al.
Oncoimmunology
|
March 17, 2023
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
Benjamin C Park, Sathya Narayanan, Alexander Gavraldis, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Nature Medicine
|
August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Cancer Immunology Research
|
December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma
Jeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Cancer Immunology Research
|
August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
Douglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 18, 2021
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study
Girish S Naik, Elizabeth I Buchbinder, Justine V Cohen, et al.
Cancer Discovery
|
March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
Page
of 33
Search research articles
Search
Showing results (161-170 of 327) with videos related to
Sort By:
Page
of 33
The Journal of Molecular Diagnostics : JMD
|
December 4, 2015
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma
Carrie C Lubitz, Sareh Parangi, Tammy M Holm, et al.
Journal of the American Academy of Dermatology
|
March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study
Bonnie W Leung, Guihong Wan, Nga Nguyen, et al.
Oncoimmunology
|
March 17, 2023
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
Benjamin C Park, Sathya Narayanan, Alexander Gavraldis, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Nature Medicine
|
August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
Che-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Cancer Immunology Research
|
December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma
Jeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Cancer Immunology Research
|
August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
Douglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 18, 2021
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study
Girish S Naik, Elizabeth I Buchbinder, Justine V Cohen, et al.
Cancer Discovery
|
March 18, 2016
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A Miller, Madeleine J Oudin, Ryan J Sullivan, et al.
Page
of 33